Therefore, STING agonists can be used in combination with ICIs, since they convert cold HCC into hot HCC by release of Type I IFNs, recruitment and activation of immune cells, enhancement of T-cell activity via CD8+ T-cell infiltration, and reprogramming of macrophages [126]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.